Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Debt: 2010-2025

Historic Total Debt for Arrowhead Pharmaceuticals (ARWR) over the last 11 years, with Sep 2025 value amounting to $254.9 million.

  • Arrowhead Pharmaceuticals' Total Debt fell 35.17% to $254.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $254.9 million, marking a year-over-year decrease of 35.17%. This contributed to the annual value of $254.9 million for FY2025, which is 35.17% down from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Total Debt stood at $254.9 million for FY2025, which was down 35.17% from $393.2 million recorded in FY2024.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Total Debt peaked at $393.2 million during FY2024, and registered a low of $254.9 million during FY2025.
  • For the 2-year period, Arrowhead Pharmaceuticals' Total Debt averaged around $324.0 million, with its median value being $324.0 million (2024).
  • Data for Arrowhead Pharmaceuticals' Total Debt shows a maximum YoY plummeted of 35.17% (in 2025) over the last 5 years.
  • Yearly analysis of 2 years shows Arrowhead Pharmaceuticals' Total Debt stood at $393.2 million in 2024, then tumbled by 35.17% to $254.9 million in 2025.